Literature DB >> 28408209

Role of miR-34a in TGF-β1- and Drug-Induced Epithelial-Mesenchymal Transition in Alveolar Type II Epithelial Cells.

Mikihisa Takano1, Chinami Nekomoto2, Masashi Kawami2, Ryoko Yumoto2.   

Abstract

Epithelial-mesenchymal transition (EMT) of alveolar type II epithelial cells may play an important role in the pulmonary fibrosis induced by drugs such as bleomycin (BLM) and methotrexate (MTX). In this study, we examined the role of microRNAs (miRNAs) in drug-induced EMT using RLE/Abca3, a cell line having alveolar type II cell-like phenotype. Based on the screening using miRNA microarray analysis, it was found that the expression of some miRNAs, such as miR-34a, was increased by transforming growth factor (TGF)-β1 and BLM. An increase in miR-34a expression due to TGF-β1, BLM, and MTX was also observed in real-time PCR analysis. Therefore, miR-34a was focused upon in further studies. The expression of nectin-1 mRNA and protein, a possible target of miR-34a, was decreased by the treatment with TGF-β1, BLM, and MTX. In addition, when RLE/Abca3 cells were transfected with miR-34a mimic, the expression of nectin-1 mRNA and Abca3 mRNA, another target of miR34a, decreased significantly. Furthermore, the mRNA expression of cytokeratin 19, an epithelial marker, decreased, whereas that of α-smooth muscle actin, a mesenchymal marker, increased in the cells transfected with miR-34a mimic. These results suggest that miR-34a is involved in drug-induced EMT in alveolar epithelial cells, and possibly in lung fibrosis.
Copyright © 2017 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cell biology; epithelial; microarrays; pulmonary; toxicology

Mesh:

Substances:

Year:  2017        PMID: 28408209     DOI: 10.1016/j.xphs.2017.04.002

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

1.  Pterostilbene prevents hepatocyte epithelial-mesenchymal transition in fructose-induced liver fibrosis through suppressing miR-34a/Sirt1/p53 and TGF-β1/Smads signalling.

Authors:  Lin Song; Tian-Yu Chen; Xiao-Juan Zhao; Qiang Xu; Rui-Qing Jiao; Jian-Mei Li; Ling-Dong Kong
Journal:  Br J Pharmacol       Date:  2019-04-24       Impact factor: 8.739

Review 2.  MicroRNA-34a: A Novel Therapeutic Target in Fibrosis.

Authors:  Min Zhao; Qin Qi; Shimin Liu; Rong Huang; Jiacheng Shen; Yi Zhu; Jing Chai; Handan Zheng; Huangan Wu; Huirong Liu
Journal:  Front Physiol       Date:  2022-06-20       Impact factor: 4.755

3.  MiR-5100 targets TOB2 to drive epithelial-mesenchymal transition associated with activating smad2/3 in lung epithelial cells.

Authors:  Chun-Yan Li; Ya-Hong Wang; Zi-Ying Lin; La-Wei Yang; Sheng-Lan Gao; Tie Liu; Bao-An Zou; Zhan-Chun Pan; Ze-Qing Song; Gang Liu
Journal:  Am J Transl Res       Date:  2017-10-15       Impact factor: 4.060

4.  Hyperoxia causes miR-34a-mediated injury via angiopoietin-1 in neonatal lungs.

Authors:  Mansoor Syed; Pragnya Das; Aishwarya Pawar; Zubair H Aghai; Anu Kaskinen; Zhen W Zhuang; Namasivayam Ambalavanan; Gloria Pryhuber; Sture Andersson; Vineet Bhandari
Journal:  Nat Commun       Date:  2017-10-27       Impact factor: 14.919

5.  miR-34a-5p Attenuates EMT through targeting SMAD4 in silica-induced pulmonary fibrosis.

Authors:  Yuanmeng Qi; Ahui Zhao; Peiyan Yang; Luheng Jin; Changfu Hao
Journal:  J Cell Mol Med       Date:  2020-09-14       Impact factor: 5.310

6.  Characterization of miR-34a-Induced Epithelial-Mesenchymal Transition in Non-Small Lung Cancer Cells Focusing on p53.

Authors:  Masashi Kawami; Shinnosuke Takenaka; Mizuki Akai; Ryoko Yumoto; Mikihisa Takano
Journal:  Biomolecules       Date:  2021-12-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.